| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Phase 2a | — | Subscribe to access the data. | Nanomedicine | Rare Diseases | ||
Top-line Data example | Phase 2a | — | Subscribe to access the data. | Nanomedicine | Rare Diseases | ||
Top-line Data example | Phase 2a | — | Subscribe to access the data. | Nanomedicine | Rare Diseases |
Recent Updates
Recently added Catalysts
HOOKIPA Pharma Inc.$1.13
+0.01 (+0.48%)
C 42Pipeline Score Undervalued Biotech · Clinical
Market Cap
10.25 M
EPS
-5.93
P/E Ratio
-
Value Trade
10.64 K
SEC Financials
Q1 2025Dilution Risk
Revenue
2.00 M
R&D Expenses
12.86 M
Operating CF
52.00 K
Total Assets
61.26 M
Total Liabilities
27.18 M
Equity
34.08 M
-6.63 %
Week
-26.93 %
1 Month
-43.6 %
3 Month
-55.3 %
6 Month
-99.21 %
5 Year
-99.41 %
All Time
Cash Data
Cash Position
40.28 M
Monthly Burn
-
Runway
-
Burn Trend
SEC Filing
May 15, 2025
Overview
Volume
9.27 K
52 Week Range
0.72 - 5.66
% held by Insiders
42.75 %
% held by Institutions
20.2 %
Enterprise Value
-29.53 M
Total Shares
9.80 M
Short %
1.87 %
Float Shares
6.85 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-11-09 | Eseba-vec (HB200) | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-11-09 | Eseba-vec (HB200) | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-11-09 | Eseba-vec (HB200) | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
C42
Pipeline Score $114M
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored11.0x
rNPV / MCap Top 64%
Micro Cap (rank 333 of 923)
Percentile RankHOOKIPA Pharma Inc. carries a moderate pipeline score (42/100), with $454M risk-adjusted pipeline value, led by HB-201 administration. in HPV-Related Squamous Cell Carcinoma (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HB-201 administration. Small molecule | HPV-Related Squamous Cell Carcinoma | Phase 1 | NCT04180215 | 5% | $233M | COMPLETED | 198 | - | - | Jan 9, 2025 | - | Sep 15, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HB-200 | recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer | Phase 2 | 2024-06-04 | ORR: 37%; CR: 11%; DCR: 69%; subset ORR: 53%; subset CR: 18%; subset DCR: 82%; median follow up: 8.4 months Read More | HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society for Clinical Oncology 2024 Annual Meeting Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head Read More | |
HB-200 | recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer | Phase 2 | 2024-06-04 | ORR: 37%; CR: 11%; DCR: 69%; subset ORR: 53%; subset CR: 18%; subset DCR: 82%; median follow up: 8.4 months Read More | HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society for Clinical Oncology 2024 Annual Meeting Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head Read More | |
HB-200 | recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer | Phase 2 | 2024-06-04 | ORR: 37%; CR: 11%; DCR: 69%; subset ORR: 53%; subset CR: 18%; subset DCR: 82%; median follow up: 8.4 months Read More | HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society for Clinical Oncology 2024 Annual Meeting Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HOOK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HOOK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How HOOK ranks across every disease it competes inCompetitive Position is a premium feature
See how HOOK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial